Mikkel W Pedersen Selected Research

futuximab

1/2020	Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation.
7/2018	Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
4/2018	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.
6/2015	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.
12/2013	Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.
10/2013	Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mikkel W Pedersen Research Topics

Disease

16	Neoplasms (Cancer) 01/2020 - 02/2004
4	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 10/2013
3	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021 - 12/2013
1	Residual Neoplasm 01/2020
1	Glioblastoma (Glioblastoma Multiforme) 07/2018
1	Breast Neoplasms (Breast Cancer) 03/2015
1	Lung Neoplasms (Lung Cancer) 12/2013
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2013
1	Carcinogenesis 09/2013
1	Glioma (Gliomas) 05/2008
1	Embryonal Carcinoma 05/2008
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 04/2003

Drug/Important Bio-Agent (IBA)

7	ErbB Receptors (EGF Receptor)IBA 01/2020 - 02/2004
6	futuximabIBA 01/2020 - 10/2013
5	LigandsIBA 01/2020 - 02/2004
5	AntibodiesIBA 01/2020 - 10/2013
3	Cetuximab (Erbitux)FDA Link 01/2021 - 10/2013
3	epidermal growth factor receptor VIIIIBA 07/2018 - 02/2004
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 11/2017
2	human ERBB2 proteinIBA 01/2020 - 10/2016
2	Monoclonal AntibodiesIBA 04/2018 - 10/2013
2	EpitopesIBA 12/2017 - 10/2013
2	Trastuzumab (Herceptin)FDA Link 11/2017 - 03/2015
1	Insulin-Like PeptidesIBA 01/2021
1	Cisplatin (Platino)FDA LinkGeneric 01/2020
1	Cell Surface ReceptorsIBA 01/2020
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2020
1	Circulating Tumor DNAIBA 04/2018
1	Messenger RNA (mRNA)IBA 11/2017
1	Neuregulin-1 (Neuregulin 1)IBA 11/2017
1	Pharmaceutical PreparationsIBA 11/2017
1	Neutralizing AntibodiesIBA 11/2017
1	Panitumumab (Vectibix)FDA Link 06/2015
1	pertuzumabIBA 03/2015
1	Caspase 3 (Caspase-3)IBA 10/2013
1	tyrosine receptor (receptor, tyrosine)IBA 09/2013
1	Phosphotransferases (Kinase)IBA 09/2013
1	Transcription Factors (Transcription Factor)IBA 05/2008
1	OligonucleotidesIBA 04/2003

Therapy/Procedure

6	Therapeutics 01/2020 - 09/2013
2	Aftercare (After-Treatment) 01/2020 - 11/2017
1	Radiotherapy 12/2013
1	Drug Therapy (Chemotherapy) 10/2013